Expected Upcoming Milestones
- Top-line results from Phase 2b GALACTIC-1 trial (IPF) in mid-2023.
- Interim safety data from Phase 2a GALLANT-1 trial (NSCLC) by Q1 2023.
- Initiation of Phase 2 investigator-initiated GB1211 oncology trial (melanoma and HNSCC) by Providence Cancer Institute in 2023.
"The recent release of positive results from two clinical trials, our Phase 1b/2a GULLIVER-2 trial in decompensated liver cirrhosis and our Phase 2a MYLOX-1 trial in myelofibrosis, has created significant momentum for Galecto and our team," said Galecto CEO Hans T. Schambye, M.D., Ph.D. "Galectin-3 and LOXL2 play a central role in fueling key pathological pathways in fibrosis, and the encouraging results from both of these trials provides further evidence and strengthens our belief that the inhibition of galectin-3 and LOXL2 are crucial to reducing fibrosis and potentially modifying disease. We look forward to 2023, where we expect to announce top-line results from our Phase 2b GALACTIC-1 trial in idiopathic pulmonary fibrosis (IPF) in mid-2023 and our Phase 2a GALLANT-1 trial in non-small cell lung cancer (NSCLC) in the second half of 2023."